MaxCyte, Inc. (MXCT)

MaxCyte's stock price has significantly decreased over the past six months. In March 2026, the company reported a decrease in total revenue for FY2025 and provided lower revenue guidance for 2026. Parmeet Ahuja was appointed as the new CFO, and the company received a Nasdaq minimum bid price non-compliance notice. February 2026 saw the unveiling of ExPERT DTx™. Preliminary FY25 results in January 2026 indicated revenue softness. In November 2025, Q3 earnings showed a decrease in total revenue, and a CFO transition was announced.

Explicit information regarding demand seasonality is not available; however, demand is dependent on research and development spending by biopharmaceutical companies and academic institutions. Revenue from Strategic Platform Licenses (SPLs) can be uncertain. The company expects capital conservation by biotechs to stabilize in the second half of 2026. Q1 is typically the lightest quarter for core revenue, with the second half of the year being more heavily weighted.

MaxCyte, Inc. is a clinical-stage cell therapy platform company specializing in flow electroporation technology for delivering macromolecules into living cells. Operating in the Biotechnology and Life Sciences industry, its core offering is the ExPERT™ platform, including instruments like ExPERT ATx, STx, GTx, VLx, and DTx. Revenue is generated through instrument sales, reagents, disposables, and licensing agreements. MaxCyte's technology enables non-viral delivery with high efficiency and scalability and was used in the development of CASGEVY®. The company also provides SeQure DX® gene editing risk assessment services.

Headquartered in Rockville, Maryland, MaxCyte has a global presence with offices and service centers in North America, Europe, and Asia. Its new facility in Rockville increases manufacturing capacity and lab space. The company partners with academic institutions and biopharmaceutical companies worldwide.

MaxCyte has maintained a reputation as a leading cell-engineering company. The company celebrated its 25th anniversary in November 2024. MaxCyte's Flow Electroporation technology played a crucial role in the development of CASGEVY®. The launch of the ExPERT DTx™ platform demonstrates continued innovation. MaxCyte has signed multiple SPL agreements with cell therapy developers.

As of April 2026, institutions hold a significant portion of MaxCyte's stock. Major institutional owners include BlackRock, Inc., Mirabella Financial Services Llp, Vanguard Group Inc, Vitruvian Partners LLP, and Morgan Stanley. Individual insiders hold a small percentage of shares, and insiders have sold more stock than they have bought in the past three months.